A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma

Journal of Thoracic Disease

Volumn 4, Issue 1, 2012, Pages 58-62

  Ling, Yang ^a   Chen, Jia ^b   Tao, Min ^c   Chu, Xiaoyuan ^d   Zhang, Xizhi ^e  

^a School of Electronic and Information Engineering Soo Chow University   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c SOOCHOW UNIVERSITY   (China)

^d NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^e NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

Author keywords

Chemotherapy; Esophageal cancer; Nimotuzumab; Squamous cell carcinoma

Indexed keywords

EID: 84861984671     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2011.08.02     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Das P. Esophageal cancer: Is preoperative chemoradiation the new standard? J Gastrointest Oncol 2010;1:68-9.
3. Kleinberg L. Does postoperative radiation therapy benefit patients with esophageal cancer? J Gastrointest Oncol 2010;1:70-1.
4. Jabbour SK, Thomas CR Jr. Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol 2010;1:102-11.
5. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001;31:419-23.
6. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-20.
7. Honda M, Miura A, Izumi Y, Kato T, Ryotokuji T, Monma K, et al. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis Esophagus 2010;23:641-5.
8. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006;118:1173-80.
9. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005;93:107-15.
10. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007;109:658-67.
11. Ozawa S, Ueda M, Ando N, Shimizu N, Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 1989;63:2169-73.
12. Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 1997;16:281-94.
13. Gibson AD, Lamerdin JA, Zhuang P, Baburaj K, Serpersu EH, Peterson CB. Orientation of heparin-binding sites in native vitronectin. Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional. J Biol Chem 1999;274:6432-42.
14. Patnaik SK, Mallick R, Yendamuri S. MicroRNAs and esophageal cancer. J Gastrointest Oncol 2010;1:55-63.
15. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637-42.
16. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-33.
17. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997;3:71-81.
18. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002;101:567-75.
19. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advancedhead and neck cancer patients. J Clin Oncol 2004;22:1646-54.
20. Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005;10:760-1.
21. Hopkins S, Yang GY. Positron Emission Tomography's Utility in Esophageal Cancer Management. J Thorac Dis 2009;1:29-33.
22. Anderson SE, Minsky BD, Bains M, Kelsen DP, Ilson DH. Combined modality therapy in esophageal cancer: the Memorial experience. Semin Surg Oncol 2003;21:228-32.
23. Wagner TD, Khushalani N, Yang GY. Clinical T2N0M0 carcinoma of thoracic esophagus. J Thorac Dis 2010;2:36-42.
24. Yang GY. Helical Tomotherapy For Radiochemotherapy In Esophageal Cancer: A Preferred Plan? J Thorac Dis 2009;1:3-4.
25. Chen YJ, Kernstine KH, Shibata S, Lim D, Smith DD, Tang M, et al. Imageguided Radiotherapy Of Esophageal Cancer By Helical Tomotherapy: Acute Toxicity And Preliminary Clinical Outcome. J Thorac Dis 2009;1:11-16.
26. Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res 2008;2:85-92.
27. Boone J, van Hillegersberg R, Offerhaus GJ, van Diest PJ, Borel Rinkes IH, Ten Kate FJ. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus 2009;22:496-504.
28. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41-8.
29. Diaz Miqueli A, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 2007;26:423-31.
30. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-9.
31. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13:5869-75.
32. Dobelbower MC, Russo SM, Raisch KP, Seay LL, Clemons LK, Suter S, et al. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 2006;17:95-102.